Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Target Price at $86.64

The Cooper Companies, Inc. (NASDAQ:COO) has been given an average rating of “Moderate Buy” by the twelve analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $86.6364.

COO has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $94.00 target price on shares of Cooper Companies in a research note on Thursday, August 28th. Morgan Stanley set a $76.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a research note on Thursday, August 28th. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. Stifel Nicolaus lowered their price objective on Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. lowered their price objective on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating on the stock in a research note on Thursday, August 28th.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $67.22 on Tuesday. The firm has a market cap of $13.36 billion, a P/E ratio of 33.11, a price-to-earnings-growth ratio of 1.69 and a beta of 0.97. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $112.29. The business’s 50 day moving average is $70.79 and its 200-day moving average is $75.31.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Equities research analysts predict that Cooper Companies will post 3.98 earnings per share for the current year.

Cooper Companies declared that its board has approved a share buyback program on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In related news, COO Gerard H. Warner III acquired 1,450 shares of the stock in a transaction on Friday, September 5th. The shares were purchased at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the purchase, the chief operating officer directly owned 18,319 shares in the company, valued at approximately $1,268,224.37. The trade was a 8.60% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Brian G. Andrews acquired 1,525 shares of the stock in a transaction on Tuesday, September 2nd. The shares were bought at an average price of $65.68 per share, for a total transaction of $100,162.00. Following the purchase, the executive vice president owned 22,191 shares in the company, valued at approximately $1,457,504.88. This trade represents a 7.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 15,975 shares of company stock worth $1,079,566 in the last quarter. Insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

A number of large investors have recently modified their holdings of COO. Sustainable Growth Advisers LP acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at $240,881,000. Ameriprise Financial Inc. boosted its holdings in shares of Cooper Companies by 98.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after purchasing an additional 1,683,561 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Cooper Companies by 7,723.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,569,512 shares of the medical device company’s stock valued at $111,686,000 after purchasing an additional 1,549,450 shares in the last quarter. Findlay Park Partners LLP boosted its holdings in shares of Cooper Companies by 312.5% in the 2nd quarter. Findlay Park Partners LLP now owns 1,815,900 shares of the medical device company’s stock valued at $129,219,000 after purchasing an additional 1,375,657 shares in the last quarter. Finally, Soundwatch Capital LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at $607,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.